Research Progress on Clinical Significance of Peripheral Blood CD34 + Cells Count in Autologous Stem Cell Mobilization and Collection

汪靖,王苓,王丽宁,姜杰玲,胡炯
DOI: https://doi.org/10.3760/cma.j.cn511693-20220124-00011
2022-01-01
Abstract:Autologous hematopoietic stem cell transplantation (auto-HSCT) is widely used in clinical treatment of blood system diseases, but some patients still face treatment failure. The content of hematopoietic stem cells (HSC) in peripheral blood is negligible, and it must be mobilized to promote the release of HSC from bone marrow into peripheral blood. HSC mobilization is a key process of auto-HSCT, and the mobilization efficiency and collection volume have significant impacts on auto-HSCT success and post-transplant outcomes. Low peripheral blood CD34 + cell counts due to poor mobilization capacity are one of the main reasons for auto-HSCT failure. The insufficient number of reinfused HSC in auto-HSCT may affect the long-term prognosis of patients. The low count of peripheral blood CD34 + cells count due to poor mobilizers is the principal cause for auto-HSCT failure. Preemptive treatment with new HSC mobilization agent plerixafor before collection can effectively reduce the mobilization failure rate. This article intends to review application status of auto-HSCT, the status of HSC mobilization, and role of peripheral blood CD34 + count in HSC collection, in order to provide a theoretical basis for identifying patients with poor mobilization in clinical practice and guiding reasonable preemptive intervention with plerixafor.
What problem does this paper attempt to address?